Abstract
Introduction Therapy-related leukemias (TRL) are neoplasms that occur as a late consequence after exposure to certain cytotoxic agents or radiation. Several cytotoxic agents have been implicated in the development of TRL. These include alkylating agents (melphalan, cyclophosphamide); platinum compounds (cisplatin, carboplatin); and topoisomerase-2 inhibitors, such as etoposide, daunorubicin, and mitoxantrone. The latency period between exposure and the development of TRL varies from a few months to several years, depending on the cytotoxic agent. TRL after exposure to alkylating agents is thought to typically develop after a latency of more than 3 years; whereas, that which develops with use of opoisomerase-2 inhibitors typically present within 1 to 3 years. Cisplain, as well as carboplatin, used in the treatment of a wide variety of alignancies, have previously been linked with TRL, whereas, the role f oxaliplatin (1,2-diaminocyclohexane oxalato platinum) (OXP), a
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
